

Paola Circosta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1557757/publications.pdf>

Version: 2024-02-01

33
papers

1,592
citations

430874

18
h-index

477307

29
g-index

35
all docs

35
docs citations

35
times ranked

2811
citing authors

#	ARTICLE	IF	CITATIONS
1	Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2001, 97, 2777-2783.	1.4	299
2	MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. <i>Leukemia Research</i> , 1999, 23, 127-136.	0.8	233
3	Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5090-5095.	7.1	147
4	CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. <i>Blood</i> , 2003, 101, 1962-1969.	1.4	139
5	Chronic myeloid leukemia stem cells. <i>Leukemia</i> , 2019, 33, 1543-1556.	7.2	127
6	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , 2016, 127, 221-232.	1.4	97
7	High Basal γ H2AX Levels Sustain Self-Renewal of Mouse Embryonic and Induced Pluripotent Stem Cells. <i>Stem Cells</i> , 2012, 30, 1414-1423.	3.2	75
8	miR-223 Is a Coordinator of Breast Cancer Progression as Revealed by Bioinformatics Predictions. <i>PLoS ONE</i> , 2014, 9, e84859.	2.5	61
9	Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- <i>a</i>]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6034-6055.	6.4	57
10	Leukemia-Derived Immature Dendritic Cells Differentiate into Functionally Competent Mature Dendritic Cells That Efficiently Stimulate T Cell Responses. <i>Journal of Immunology</i> , 2004, 173, 2855-2865.	0.8	48
11	Nanocarriers as Magic Bullets in the Treatment of Leukemia. <i>Nanomaterials</i> , 2020, 10, 276.	4.1	38
12	T Cell Receptor (TCR) Gene Transfer with Lentiviral Vectors Allows Efficient Redirection of Tumor Specificity in Naive and Memory T Cells Without Prior Stimulation of Endogenous TCR. <i>Human Gene Therapy</i> , 2009, 20, 1576-1588.	2.7	34
13	The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. <i>Experimental Hematology</i> , 2003, 31, 495-503.	0.4	31
14	Bone marrow microenvironment: The guardian of leukemia stem cells. <i>World Journal of Stem Cells</i> , 2019, 11, 476-490.	2.8	29
15	The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1003.	3.7	21
16	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. <i>Cancers</i> , 2021, 13, 1311.	3.7	21
17	The molecular and functional characterization of clonally expanded CD8+ TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA). <i>Clinical Immunology</i> , 2014, 152, 152-163.	3.2	20
18	Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- <i>a</i>]pyridine Scaffold: SAR of the Biphenyl Moiety. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5404-5428.	6.4	19

#	ARTICLE	IF	CITATIONS
19	Clonal CD8+ TCR-V β 2 expanded populations with effector memory phenotype in Churg Strauss Syndrome. <i>Clinical Immunology</i> , 2008, 128, 94-102.	3.2	18
20	Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1650-1657.	3.6	18
21	Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition. <i>Human Gene Therapy</i> , 2015, 26, 220-231.	2.7	15
22	Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34+ cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors. <i>Journal of Biotechnology</i> , 2011, 156, 218-226.	3.8	14
23	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. <i>OncImmunology</i> , 2018, 7, e1341032.	4.6	11
24	Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells. <i>Journal of Clinical Medicine</i> , 2021, 10, 5805.	2.4	7
25	Lentiviral Transduction of Primary Myeloma Cells with CD80 and CD154 Generates Antimyeloma Effector T Cells. <i>Human Gene Therapy</i> , 2005, 16, 445-456.	2.7	5
26	Immature CML cells implement a BMP autocrine loop to escape TKI treatment. <i>Translational Cancer Research</i> , 2018, 7, S722-S725.	1.0	3
27	TCR transfer induces TCR-mediated tonic inhibition of RAG genes in human T cells. <i>Molecular Immunology</i> , 2011, 48, 1369-1376.	2.2	2
28	An Ig Transmembrane Domain Motif Improves the Function of TCRs Transduced in Human T Cells: Implications for Immunotherapy. <i>Journal of Immunotherapy</i> , 2019, 42, 97-109.	2.4	2
29	Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	1
30	Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect. <i>Immunotherapy</i> , 2018, 10, 753-767.	2.0	0
31	A CD8+ T-Cell Clone Directed Against AML Blasts that Recognizes a Tumor Specific Antigen Expressed Also by Solid Tumors. <i>Blood</i> , 2010, 116, 4289-4289.	1.4	0
32	Retargeting of Cytokine-Induced Killer (CIK) Cells with Molecularly Engrafted T-Cell Receptors (TCR): A Preclinical in Vitro and In Vivo Study. <i>Blood</i> , 2011, 118, 1917-1917.	1.4	0
33	Molecular and Functional Analysis of Peripheral Lymphocytes in Churg Strauss Syndrome Reveals Several Monoclonal Expansions of CD8+ Cells with a Th1/Proinflammatory Profile. <i>Blood</i> , 2012, 120, 1051-1051.	1.4	0